NASDAQ: RYTM
Rhythm Pharmaceuticals, Inc.
Healthcare · Biotechnology
Market Cap
$6.64B
52w High
$122.20
52w Low
$60.80
P/E
-32.46
Volume
1.46M
Outstanding Shares
68.59M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 57.43% over the last year. Revenue grew 58.67% over the trailing twelve months. Operating margin moved from -126.13% to -90.89%. Free cash flow declined 6.15% over the trailing twelve months.
What the market seems to be pricing
The stock is trading toward the richer end of its historical P/S range (69th percentile) while business metrics are improving. More of the upside is already embedded in the multiple now.
What would invalidate this read
Operating margin is at -90.89% — continued expansion would be needed to justify the premium. Revenue growth of 58.67% is encouraging, but any deceleration puts the stretched multiple at risk. This read changes if revenue, margins, and cash flow continue to improve faster than expected — in that case the richer multiple could still prove conservative.
Company profile
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
20
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 4, 2026
Q3 FY26 · EPS est -$0.82 · Revenue est $67.53M
View